Cystic Fibrosis

Cystic Fibrosis


WHEREAS, cystic fibrosis is a multi-system genetic disease primarily affecting the lungs and digestive system;

WHEREAS, one in every 3,600 children born in Canada has cystic fibrosis, making it the most common fatal genetic disease affecting Canadian children and young adults;

WHEREAS, there is no cure for cystic fibrosis, but the drug Kalydeco is the first medication that has shown success in targeting the underlying genetic cause of cystic fibrosis;

WHEREAS, this drug helps improve the function of the defective protein, leading to better lung function, weight gain, and lower sweat chloride levels. For a CF patient with the specific G551D mutation, access to Kalydeco could lead to a healthier, longer life; and

WHEREAS, Kalydeco has been approved by Health Canada, but the approximately $300,000 annual cost makes it an unaffordable treatment option for the overwhelming majority of Ontario families.

THEREFORE, we the undersigned petition the Legislative Assembly of Ontario as follows: That the Minister of Health and Long-Term Care take immediate action to expedite listing Kalydeco on the province’s drug formulary so this treatment is available to Ontario families as it is to those in several countries including the Republic of Ireland and the United Kingdom.

Will you sign?

Be the first to comment